MindImmune Therapeutics

MindImmune Therapeutics is a private, preclinical-stage biotech founded in 2018 and headquartered in San Diego, CA. The company is pioneering an immunomodulatory approach to neurodegenerative diseases, with an initial focus on Alzheimer's disease. Its core technology involves targeting a specific innate immune cell recruited into the brain that drives damaging neuroinflammation. The company is advancing its lead candidate, MITI-101, towards an IND, supported by a $30M Series A financing round and a leadership team with extensive CNS drug discovery experience.

Platform targeting the recruitment of specific peripheral innate immune cells into the brain to halt neuroinflammation in neurodegenerative disease.

MindImmune operates in the competitive Alzheimer's disease space, competing with approved anti-amyloid therapies and numerous late-stage candidates. Its specific neuroimmunology approach faces competition from other companies targeting innate immunity or inflammation in the CNS, but its focus on peripheral immune cell recruitment is a distinct angle.